17b-Oestradiol (E2) and its receptors (ERa and ERb) are important regulators of physiological and pathological processes in the cardiovascular system. ER act in concert with other regulatory factors mediating oestrogenic effects. However, the underlying mechanisms modulating ER transcriptional activity are not fully elucidated. To gain better understanding of E2-induced ERa action in the human heart, we aimed to identify and functionally analyse interaction partners of ERa.
Introduction
17b-Oestradiol (oestrogen, E2) influences a number of physiological and pathological processes in mammals, including the cardiovascular system. 1 -4 However, the underlying molecular mechanisms are still not fully understood. E2 mediates its effects predominantly via oestrogen receptor a (ERa) and b (ERb), which are members of the nuclear receptor superfamily. 5 The ER act as ligand-induced transcription factors and regulate the expression of E2-target genes (genomic effects). 6 The ER are expressed in human and rodent hearts, 7, 8 and regulate upon E2 activation the expression of relevant E2-target genes, such as connexin 43 (Cx43), matrix metalloproteinases, and atrial natriuretic peptide (ANP), which play a role in the pathogenesis of myocardial diseases. 7, 9, 10 It is generally accepted that ER require a number of co-regulatory proteins whose cell-specific expression may explain some of the distinct cellular actions of E2. 11 The transcriptional activity of ER can be enhanced or suppressed by regulatory proteins called co-activators and co-repressors, respectively. Most of these co-regulators interact with ER through their highly conserved LXXLL motif, where L is leucine and X is any amino acid. 12, 13 So far, only few ER co-regulators have been described in the human heart. To gain a better understanding of E2-mediated ER action in the human heart, we focused in this work on ERa and aimed to characterize and functionally analyse novel interaction partners of ERa. We identified atrial natriuretic peptide precursor A (NPPA), the precursor of ANP, a well-known marker of myocardial hypertrophy (MH) and heart failure (HF), 14 as a novel co-repressor of ERa action in the human heart. Our findings suggest that the interaction of ERa and NPPA contributes, at least partly, to the E2-mediated regulation of cardiomyocyte gene expression and function.
Methods

Study approval
The use of human cardiac tissues was approved by the ethical committee of Charité University Hospital and followed the principles of the Declaration of Helsinki. 
Cell culture and treatment
For in-vitro investigations, we used a human cardiomyocyte-like cell line, AC16 cells, 15 derived from adult female LV heart tissue, and neonatal rat cardiac myocytes (NNRCM) isolated from 1 to 3-day-old SpragueDawley rats. 
Plasmid construction
Constructs were generated by PCR and standard cloning techniques. Detailed description of how the vectors were constructed and the list of primers can be found under Supplementary material online, Table S1 .
Yeast two-hybrid screen and b-galactosidase assay
Yeast two-hybrid (Y2H) screening was performed using the BD Matchmaker Two-Hybrid System 2 according to the manufacturer's instructions (CLONTECH). Full-length human (h)ERa-pBTM116 and hERa-EF-pBTM116 constructs were used as baits to screen 3.5 × 10 6 clones from a human heart BD Matchmaker TM cDNA library in Saccharomyces cerevisiae strain L40. Two independent large screens were carried out on selection plates lacking tryptophan, histidine, leucine, and uridine; and containing 20 -80 mmol/L 3-amino-triazole and E2 (10 28 mol/L). Growing colonies were picked and patched on selection plates without E2. Only yeast colonies that showed E2-dependent growth were selected for further analysis. Plasmids were isolated and prey cDNA inserts were sequenced and identified using NCBI Blast. cDNAs from positive clones were subcloned into appropriate vectors for subsequent experiments. The E2-dependent interaction of hERa and identified proteins was confirmed by independent 1:1 Y2H retransformation assays of the prey and bait plasmids into L40 yeast. To validate the interaction, the positive colonies were also assayed for b-galactosidase activity using a common b-Gal colony-lift filter assay. For each identified interaction partner, false positive tests involving empty vector were conducted to eliminate spurious interactions according to manufacturer's recommendations.
Transient transfections and reporter assays
The transient transfection/dual-luciferase reporter assays were carried out as previously described. 16 Briefly, AC16 cells were plated in 12-well plates 
Gene expression analysis
Total RNA isolation and quantitative real-time polymerase chain reaction (qRT-PCR) was conducted as previously described. 16 Primer sequences used for amplification are listed in Supplementary material online, Table S1 .
Immunoblot and co-immunoprecipitation analyses
For Western blot analysis, AC16 cell extracts or whole extracts of LV tissues isolated from female ERaKO mice 17 (n ¼ 7) or wild-type littermates (n ¼ 6) were separated by SDS -polyacrylamide gel electrophoresis as previously described. 16 Western blot analysis was performed using rabbit polyclonal antibodies against NPPA (FL-153, Santa Cruz) and Cx43 (ab11370, Abcam), and for normalization rabbit polyclonal antibody against actin [(I-19)-R; Santa Cruz]. Specific bands were visualized using the ECL TM Plus detection kit (GE Healthcare). Band intensities were quantified with the ImageJ software (Version 1.37, Wayne Rasband, NIH). Co-immunoprecipitation (Co-IP) analyses were performed as described before. 18 Briefly, proteins derived from human atrial biopsies of five female patients were isolated and pre-cleared by adding protein G sepharose beads (PGS, Amersham) washed with HNTG-buffer (20 mmol/L Hepes (pH 7.5), 50 mmol/L NaCl, 10% Glycerol, and 0.1% Triton-X-100), for 2 h with gentle shaking at 48C; 500 mg pre-cleared protein lysates were incubated with different amount of an anti-ERa polyclonal antibody (MC-20, Santa Cruz) diluted in HNTG + -buffer
[HNTG-buffer plus 1 mmol/L NAF, 1 mmol/L PMSF, 1× Mini complete (Protease Inhibitor Cocktail, Roche) and 1 mmol/L Na 3 VO 4 ] for 2 h at 48C, followed by an incubation with blocked PGS (with 1% BSA) overnight with gentle shaking at 48C. After centrifugation, pellets containing antibody/antigen/PGS-complexes were washed four times with HNTG + -buffer, and finally resuspend in HNTG + -buffer and 1× reducing sample buffer (Roth). After incubation at 958C for 5 min and short centrifugation, the proteins were subjected to SDS -PAGE, which were then analysed by immunoblotting using an anti-NPPA polyclonal antibody (FL-153, Santa Cruz). For the reverse-CoIP reactions, the anti-NPPA polyclonal antibody was used and the immunoblot was incubated with the ERa antibody. As positive control served input (50 mg), and as negative controls served samples without antibody addition and protein lysate derived from LV myocardial biopsies. 
Immunofluorescence and confocal laser microscopy
Chromatin immunoprecipitation assay
AC16 cells (6 × 10 6 ) were cultured as described in Supplementary material online, Methods, and treated with E2 (10 28 mol/L) or vehicle (ethanol) for 1 h. Cellular DNA and protein interactions were cross-linked for 10 min with formaldehyde (Thermo Scientific) at a final concentration of 1%, followed by the addition of 125 mmol/L glycine for 5 min. Chromatin immunoprecipitation assay (ChIP) experiments were conducted according to a standard protocol of the Transcription Factor ChIP Kit (Diagenode). The following antibodies were used for ChIP experiments: a ChIP-grade rabbit polyclonal anti-ERa (HC-20, Santa Cruz) antibody and a normal rabbit IgG antibody (Cell Signaling Technology, Inc.) as a negative control. DNA was analysed using the Applied biosystems 7300 system and SYBR green master mix. According to manufacturer's protocol, a volume of chromatin was processed without antibody and used as total input control for qRT -PCR. As positive controls for E2 treatment, primers directed against human cMyc (cellular myelocytomatosis oncogene) and TFF1 (trefoil factor 1) promoters were used. ChIP primer sequences used in this study are listed in Supplementary material online, Table S1 .
The experiments were performed in duplicates and repeated independently at least three times. Enrichment of specific promoter regions after immunoprecipitation was calculated as a percentage of the total input chromatin following the manufacturer's instruction. Results are presented as fold change compared with values of ethanol-treated samples.
Statistics
All data are presented as mean + SEM. Statistical analysis was performed using Student's t-test or one-way ANOVA with post hoc correction. Differences with P ≤ 0.05 were considered significant.
Results
Identification of atrial natriuretic peptide precursor A as a hERa-interacting protein
To identify novel proteins interacting with hERa, we screened a human heart cDNA library using the Y2H. From two independent Y2H screens, 25 individual clones were found to contain the full coding sequence of NPPA, which interacts with hERa in the presence of E2. 1:1 retransformation experiments and b-Gal assays showed that NPPA interacts with full-length hERa (ERa-FL) and the EF domain of hERa (ERa-EF) in an E2-dependent manner ( Figure 1A ).
NPPA interacts via its LXXLL motif with hERa
To refine the binding site on NPPA, we performed 1:1 retransformation experiments and b-Gal assays using ERa-FL-pBTM116 and ERa-EF-pBTM116 as bait constructs and NPPA-WT-pACT2 or NPPA-MUT-pACT2 with mutations within the LXXLL motif, as prey constructs. Although NPPA-WT exhibited an interaction with both ERa-FL and ERa-EF in the presence of E2, NPPA-MUT was only able to interact with ERa-FL but not with ERa-EF ( Figure 1B) . These findings imply that at least two independent regions in the NPPA protein are involved in the interaction with ERa and suggest that the LXXLL motif within the NPPA selectively interacts with EF domain of ERa in the presence of E2.
ERa interacts with NPPA in the human atrium
To ascertain the ERa -NPPA interaction in a mammalian system, endogenous ERa protein from the human atrium was immunoprecipitated with an ERa antibody. Subsequent western blotting with an anti-NPPA antibody indicated that endogenous NPPA had coprecipitated with ERa ( Figure 1C ). Reverse immunoprecipitation with NPPA antibody and western blotting with an anti-ERa antibody confirmed the interaction of NPPA and ERa in the human atrium ( Figure 1D ). These results confirm the obtained data from the Y2H assays and the interaction of ERa with NPPA in the human atrium.
E2 increases the nuclear translocation and co-localization of NPPA and ERa in cardiomyocytes
To determine the subcellular localization and co-localization of NPPA and ERa in cardiomyocytes, we performed IF staining of AC16 cells, using antibodies against ERa and NPPA. In contrast to vehicle-treated AC16 cells, E2 treatment led to an increased amount of ERa and NPPA in the nuclei and cytoplasm of AC16 cells, where they co-localized ( Figure 2A ). E2 also triggered the translocation of both ERa and NPPA into nuclei of NNRCM, confirming the E2-induced nuclear translocation of these proteins in another model ( Figure 2B ).
Further IF experiments showed that as a consequence of the inhibition of activation of ERa by ICI 182 780, NPPA remained mostly in the cytoplasm and was not shuttled into the nuclei of AC16 cells ( Figure 2C ). These data indicate that the activation of ERa by E2 is on one hand a prerequisite for the interaction of ERa with NPPA and on other hand necessary for the nuclear localization/shuttling of NPPA in AC16 cells.
The LXXLL motif in NPPA is required for its E2-induced translocation into nuclei of cardiomyocytes
To test whether the LXXLL motif in NPPA plays a role in the E2/ERainduced nuclear translocation of NPPA, AC16 cells co-transfected with pFLAG-CMV4-ERa and NPPA-WT or NPPA-MUT constructs were treated with E2 or vehicle. IF analyses using antibodies against ERa or Flag and NPPA or His demonstrated, similar to the endogenous proteins, a nuclear translocation and extensive co-localization of transiently expressed ERa and NPPA proteins in the presence of E2 ( Figure 2D ). However, in cells expressing ERa/Flag and NPPA-MUT/ His, even in the presence of E2, we predominately observed a cytosolic localization with a perinuclear distribution of NPPA-MUT protein ( Figure 2E ). These data indicate that the LXXLL motif in NPPA protein is important for the interaction of ERa with NPPA and for the translocation of NPPA into nuclei of cardiomyocytes, since mutated NPPA is not able to be shuttled into the nucleus.
3.6 E2 enhances the NPPA promoter activity and NPPA gene expression in the presence of ERa
Next, we focused on functional aspects of this interaction. Based on our own and others results, 9, 19 we hypothesized that E2 induces the transcriptional activity of the NPPA promoter via ERa. To prove this hypothesis, a human NPPA promoter luciferase reporter construct (pGL2-1200-prom) was co-transfected with ERa vector into AC16 cells and subsequently treated with E2; ICI 182 780; E2 + ICI 182 780; or vehicle. E2 treatment of cells expressing both ERa and pGL2-1200-prom plasmids resulted in a significant increase in relative luciferase reporter activity ( Figure 3A) . Pre-treatment with ICI 182 780 significantly reversed the effect of E2, confirming that ERa is necessary for mediating the enhancing effect of E2 on NPPA promoter activity. Treatment with ICI 182 780 alone had no significant effects. Relative luciferase activities did not change in response to E2 in AC16 cells transfected with a NPPA-promoter construct alone.
In further experiments, we demonstrated that the expression of NPPA at mRNA and protein levels is significantly increased in the presence of E2 ( Figure 3B and C ).
E2/ERa affects NPPA levels in the heart
To confirm that ERa affects the basal NPPA expression in the heart, we measured the expression of NPPA in the hearts of female ERaKO mice. They showed significantly lower amount of NPPA in comparison with female wild-type littermates ( Figure 3D) . Thus, the stimulatory effect of E2 on NPPA expression may have been lost in female ERaKO mice due to the lack of ERa. In agreement with our previous results, these data show that ERa is a key mediator for the E2-mediated cardiac effects on NPPA expression.
3.8 NPPA inhibits E2/ERa-induced NPPA promoter activity through LXXLL motif binding of NPPA and ERa
Since our data showed that NPPA interacts with hERa through the LXXLL motif, we hypothesized that NPPA acts as a cofactor of Interaction of ERa/NPPA in the heart ERa on its own transcriptional activity. Luciferase reporter assays in AC16 cells showed that in the presence of E2/ERa, NPPA-WT dosedependently repressed E2/ERa-induced NPPA promoter activity ( Figure 4A ). These findings indicate that NPPA acts as a corepressor for ERa in the regulation of its own promoter activity in cardiomyocytes. Interestingly, co-transfection of the cells with increasing amount of NPPA-MUT did not show any changes in the E2/ERa-induced NPPA promoter activity ( Figure 4B ). These data confirm that the LXXLL motif in NPPA is required for the ligand-dependent ERa/ NPPA interaction. Furthermore, this observation reveals that the LXXLL motif of NPPA is necessary for its action as a corepressor to inhibit the E2/ERa-induced NPPA promoter activity.
E2 increases the recruitment of ERa to the NPPA promoter
We next investigated whether ERa binds directly on the NPPA promoter to regulate NPPA gene transcription using the ChIP assay. It is known that ERa binds to a specific DNA sequence, oestrogen response element (ERE), 20 located in the regulatory regions of oestrogen-responsive genes. Database analysis revealed the presence of one putative full ERE (at site 2993 bp: R1) and one ERE half-site (at site 2881: R2) within the 1200 bp of the NPPA promoter sequence. As shown in Figure 5 , in AC16 cells exposed to E2 (10 28 mol/L), the binding of ERa to both ERE on the NPPA promoter was significantly increased compared with vehicle-treated cells (3.3-and 1.75-fold induction, respectively). Since ERa was not recruited neither to a region of NPPA promoter with no ERE consensus sequence (between 2299 and 2196: R5) nor showed an association with rabbit IgG used as negative control, the recruitment of ERa was specific to the characterized regions with ERE within the NPPA promoter. However, in cells overexpressing NPPA, anti-ERa antibody failed to detect any recruitment of ERa to the target promoters NPPA, TTF1, and cMYC ( Figure 5 ). Collectively, these results clearly demonstrate that ERa is transiently recruited to the NPPA promoter in the presence of E2, and NPPA is a bona fide transcriptional repressor of ERa and inhibits the recruitment of E2/ERa to the promoters of multiple E2-responsive genes.
Functional significance of ERa and NPPA interaction in cardiomyocytes
Since we showed that the E2-induced nuclear ERa/NPPA interaction regulates the expression of the NPPA gene, we asked whether NPPA also affects the regulation of some other E2-responsive genes and/or MH/HF marker genes. In AC16 cells transfected with ERa vector, E2 significantly increased the expression levels of Cx43 (GJA1) and alpha actinin-2 (ACTN2), and decreased the expression of NFAT (nuclear factor of activated T-cells), type-1 collagen (Col I; COL1A1), type-3 collagen (Col III; COL3A1 ( Figure 6A-F) . However, co-transfection with NPPA-WT vector led to an opposite effect. Cells overexpressing NPPA-WT showed upon E2 treatment a marked reduction in the expression of Cx43 and ACTN2, and an induction of NFAT, Col I, and Col III, whereas an overexpression of NPPA-MUT did not alter the E2/ ERa transcriptional activity for these genes ( Figure 6A-D) . However, the expression of brain natriuretic peptide, transforming growth factor beta-1, and sarcoplasmic reticulum Ca 2+ ATPase were not affected in AC16 cells (Supplementary material online, Figure S1 ). In essence, these observations indicate that NPPA acts as a novel corepressor of ERa transcriptional activity for multiple E2-responsive genes in cardiomyocytes which may have a role in human cardiovascular pathophysiology.
Discussion
In the present study, we show a novel mechanism of E2 action in cardiomyocytes. We demonstrate for the first time that E2-activated ERa physically interacts with NPPA via its LXXLL motif in the cytoplasm and shuttles it into the nucleus, where both regulate the expression of multiple E2/ERa-target genes. E2/ERa bind to the promoter of the NPPA gene and induce its expression. In line with these data, myocardial NPPA expression is low in ERaKO mice. Next, we discovered a negative feedback loop: NPPA acts as a corepressor of ERa for its own gene regulation. E2-induced ERa -NPPA interaction reduces NPPA promoter activity dose-dependently in human cardiomyocytes by the inhibition of E2/ERa binding to an NPPA promoter. Additionally, NPPA also suppresses the transcriptional activity of E2/ERa on multiple genes, such as CX43, ACTN2, NFAT, Col I, and Col III, which have important roles in cardiovascular physiology and pathophysiology in AC16 cells. Due to the fact that NPPA/ANP limit cardiac hypertrophy and that E2 has cardiac hypertrophy-reducing effects, which are thought to be partly mediated via increased ANP expression, 9, 21 we suggest that the E2-induced ERa-NPPA interaction represents a novel mechanism involved in the regulation of MH and HF.
In the healthy heart, the expression of the NPPA gene is relatively high in both foetal atria and ventricles, but, after birth, the expression Interaction of ERa/NPPA in the heart is mostly restricted to the atria. 22 However, under pathological conditions, NPPA is re-expressed and up-regulated in the adult ventricles. 23 -25 The human NPPA gene encodes initially for a preprohormone of 151 amino acids (aa). After cleavage of N-terminal signal sequence (25aa), the resulting pro-hormone of 126aa (pro-ANP) is stored in atrial secretory granules. 26 Upon secretion, pro-ANP is processed into its N-terminal pro-ANP (1-98aa) and its biologically active ANP (99-126aa). 27 During pathological MH and HF, both pro-ANP and ANP are constitutively secreted from the ventricular myocardium, which makes their plasma levels a good prognostic indicator of cardiac disease. 28, 29 Several studies indicate that ANP possess an anti-hypertrophic effect in the heart and on cardiomyocytes in culture. 9, 19, 30 4.1 The LXXLL motif in NPPA is necessary for the function of E2-induced interaction of ERa and NPPA
The LXXLL motif is a characteristic binding site within many cofactors of nuclear receptors, as demonstrated to interact with nuclear receptors in a ligand-dependent manner. 13 Our analyses reveal that the LXXLL motif in NPPA is necessary and sufficient to mediate the binding of NPPA to ERa in the presence of E2 and for its translocation into nuclei of AC16 cells. Deletion of the LXXLL motif results in substantial retention of NPPA fusion protein in the cytoplasm, even in the presence of E2 and ERa ( Figure 2E) . Similar results have also been reported elsewhere for the contribution of the LXXLL motif within cofactors of nuclear receptors on nuclear localization/trafficking. 31, 32 Calderone et al. 33 also observed the translocation of NPPA into the nuclei of scar myofibroblasts. In line, Shan et al. 34 showed the physical interaction of NPPA with the apoptosis signal-regulating kinase 1, a kinase involved in the pathogenesis of HF, in HeLa cells. Closer observation of presented IF images also indicates the partial localization of NPPA in the nuclei of HeLa cells. These results along with our results provide evidence for the fact that either a portion of synthesized NPPA is not transported into the storage vesicles, or there are other processes by which the pro-ANP can be translocated from the vesicles into the nuclei of the cells. The latter possibility seems more likely. Several studies showed that ERa is localized in the membrane of intracellular vesicles in hippocampal neurons, pituitary cells, and astrocytes and E2 increases the amount and the mobilization of these ERa-immunoreactive vesicles. 35 -37 Further studies should elucidate whether ERa is also localized on the NPPA-containing vesicles in cardiomyocytes and whether upon E2 treatment, ERa is able to mobilize these vesicles towards the nucleus.
Genomic effects of E2-induced interaction of ERa and NPPA in cardiomyocytes
Our data show significant elevation of NPPA promoter activity and the expression of NPPA at mRNA and protein levels in response to Interaction of ERa/NPPA in the heart E2/ERa. The E2-induced recruitment of ERa to the NPPA promoter indicates one of the possible mechanisms how E2-activated ERa can regulate the NPPA gene expression in cardiomyocytes. In addition, we show for the first time that NPPA acts as a corepressor of ERa, and thus controls the transcription of its own gene. Surprisingly, the repressive effects of NPPA are significantly inhibited by mutation in its LXXLL motif, indicating that the LXXLL motif is important for this interaction. We propose that the interaction of ERa with NPPA causes a conformational change of ERa, so that the binding of ERa on the NPPA promoter is prevented leading to a reduced transcriptional activity of ERa (for proposed model see Supplementary material online, Figure S2 ). In agreement with these findings, an increasing level of NPPA prevents the E2/ERa-induced expression of Cx43 and ACTN2, whose dysregulation plays a role in the pathogenesis of MH. Scott et al. 38 reported that the hearts of mice lacking natriuretic peptide receptor-1 (Npr1 2/2 ) exhibit significantly increased NPPA mRNA and protein expression. Concomitantly, the expression of Cx43 mRNA and protein was down-regulated in these mice. The authors suggested that the decreased expression of Cx43 in this hypertrophy model is associated with the development of cardiac disease. These results are in accordance with our data, which show that an increased amount of NPPA has an inhibitory effect on the expression of Cx43. Additionally, an increasing level of NPPA prevents the inhibitory effect of E2/ERa on the expression of E2-target genes such as NFAT, Col I, and Col III, 39, 40 whose dysregulation also plays a role in the pathogenesis of MH. However, in NPPA-MUT overexpressing cells, the expression of these genes is not at the similar levels (excluding Cx43), as they are in cells transfected only with ERa in the presence of E2. This finding confirms that the data obtained from b-galactosidase assays which imply that at least two independent regions in the NPPA protein molecule are involved in the interaction with E2/ERa. However, based on our IF and promoter analysis, we suggest that the LXXLL motif within the NPPA is most important for recognition and contributes to the stability of the complex. Taken together; the interaction of ERa/NPPA mediates the genomic action of E2 on several E2-responsive MH/HF-associated gene(s) in cardiomyocytes, and may adjust the magnitude of the transcriptional response to different physiological and pathophysiological requirements.
Summary
We have identified a novel ERa-interacting protein, i.e. NPPA, in the human heart, which represses E2-dependently ERa transcriptional activity to regulate the expression of several E2-responsive MH/HF-associated genes. We suggest that E2 and ERa interfere with mechanisms that regulate physiological and pathophysiological processes in cardiomyocytes. Nevertheless, it is conceivable that NPPA might also interact with ERb to regulate the expression of the same or other sets of genes in cardiomyocytes, which, however, was not the focus of this study and requires further investigation. Therefore, more intense research of the cellular mechanisms in which E2 and ER are involved could substantially contribute to a better understanding of the effects of E2 and ER in the heart, and may elucidate ways to selectively enhance beneficial effects on the cardiovascular system. In this regard, NPPA could represent a therapeutic target to selectively regulate the progression of cardiovascular diseases.
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